Sattva Neelapu, MD, speculates on the future of CAR-T therapies in lymphoma
Dr. Neelapu, Department of Lymphoma and Myeloma, Division of Cancer Medicines, MD Anderson Cancer Center, speculates on the future of CAR-T therapy in the treatment of lymphoma
Keith Pratz, MD, on genetic testing in AML prior to the start of therapy
Dr. Pratz, Assistant Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, considers whether all newly diagnosed acute myeloid leukemia (AML) patients should undergo genetic testing prior to the start of therapy
Katja Weisel, MD, shares outcomes of the POLLUX and CASTOR studies from ASH 2018
Dr. Weisel, Head of the Myeloma Center, University of Tubingen, offers opinion on how the POLLUX and CASTOR studies shape her thinking regarding the use of daratumumab for multiple myeloma (MM) patients
Habte Yimer, MD, regarding the Lyra trial in newly diagnosed multiple myeloma presented at ASH 2018
Dr. Yimer, Hematologist/Oncologist, US Oncology Research Executive Council Member, Texas Oncology, discusses the impact of Lyra, a Phase 2 study investigating daratumumab in newly diagnosed multiple myeloma (MM) patients
Peter Vorhees, MD, describes what regimens are being used for multiple myeloma patients today
Dr. Vorhees, Director of Outreach and Clinical Operations, Department of Hematologic Oncology and Blood Diosrders, Levine Cancer Institute, describes what maintenance regimens are being used for multiple myeloma patients today and if that will change as a result of the clinical presentations at ASH
Peter Vorhees, MD, discusses the outcomes of the TOURMALINE-MM3 study in MM
Dr. Vorhees, Director of Outreach and Clinical Operations, Department of Hematologic Oncology and Blood Diosrders, Levine Cancer Institute, on if the outcomes of the TOURMALINE-MM3 study will change the way multiple myeloma patients who have had at least one prior therapy are treated
Peter Vorhees, MD, discusses outcomes of the ALCYONE trial in multiple myeloma patients
Dr. Vorhees, Director of Outreach and Clinical Operations, Department of Hematologic Oncology and Blood Diosrders, Levine Cancer Institute, discusses outcomes of the ALCYONE trial in transplant-ineligible newly diagnosed multiple myeloma patients
Keith Pratz, MD, comments on the Phase I study of gilteritinib presented at ASH 2018
Dr. Pratz, Assistant Professor of Oncology, Sidney Kimmel, Comprehensive Cancer Center, Johns Hopkins University, comments on the Phase I study of gilteritinib in combination with induction and consolidation therapy in subjects with newly diagnosed acute myelogenous leukemia (AML)
Sattva Neelapu, MD, considers the use of axicabtagene ciloleucel with elderly lymphoma patients
Dr. Neelapu, Department of Lymphoma and Myeloma, Division of Cancer Medicines, MD Anderson Cancer Center, discusses whether it is safe to use axicabtagene ciloleucel with elderly lymphoma patients
Keith Pratz, MD, regarding the reliability of the companion diagnostic test for FLT3
Dr. Pratz, Assistant Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, provides opinion on the reliability of the companion diagnostic test for FLT3 and whether he feels comfortable using the test to determine a course of treatment in acute myelogenous leukemia (AML)
Sattva Neelapu, MD, on real-world experience & clinical studies examining axicabtagene ciloleucel
Dr. Neelapu, Department of Lymphoma and Myeloma, Division of Cancer Medicines, MD Anderson Cancer Center, elaborates on how the real-world experience with axicabtagene ciloleucel compares with the previously published clinical studies of axicabtagene ciloleucel as shown in Abstract 91 at the 2018 ASH Annual Meeting and Exposition
Keith Pratz, MD, describes how gilteritinib fits into treatment algorithms for AML
Dr. Pratz, Assistant Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, discusses how newly approved gilteritinib will be incorporated into treatment plans for acute myelogenous leukemia (AML)
Sattva Neelapu, MD, regarding the ZUMA-1 two-year follow-up study in DLBCL
Dr. Neelapu, Department of Lymphoma and Myeloma, Division of Cancer Medicines, MD Anderson Cancer Center, tells us about the ZUMA-1 two-year follow-up study of axicabtagene ciloleucel in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) patients presented at the 2018 ASH Annual Meeting and Exposition
James McCloskey, MD, elaborates on the role of molecular testing in newly diagnosed AML
Dr. McCloskey, Interim Chief, Division of Leukemia, Hackensack University Medical Center, John Theurer Cancer Center, considers whether most hematologists and oncologists are aware that molecular tests are appropriate for newly diagnosed acute myelogenous leukemia (AML) patients
Rafael Fonseca, MD, on the effectiveness of anti-BCMA CAR-T cell therapy in multiple myeloma
Dr. Fonseca, Hematologist, Mayo Clinic, considers whether anti-BCMA CAR-T cell therapy is a promising treatment option for multiple myeloma (MM) patients
James McCloskey, MD, regarding molecular testing in acute myelogenous leukemia
Dr. McCloskey, Interim Chief, Division of Leukemia, Hackensack University Medical Center, John Theurer Cancer Center, elaborates on how molecular tests are impacting treatment decisions for acute myelogenous leukemia (AML) patients
Rafael Fonseca, MD, discusses maintenance regimens for multiple myeloma
Dr. Fonseca, Hematologist, Mayo Clinic, shares details regarding maintenance regimens for multiple myeloma (MM) and the impact of the clinical presentations from the 2018 ASH Annual Meeting and Exposition
James McCloskey, MD, considers the application of the FLT3 test in newly diagnosed AML patients
Dr. McCloskey, Interim Chief, Division of Leukemia, Hackensack University Medical Center, John Theurer Cancer Center, provides opinion on whether the FLT3 test may be applied in newly diagnosed acute myelogenous leukemia (AML)
Rafael Fonseca, MD, regarding the TOURMALINE-MM3 study in multiple myeloma
Dr. Fonseca, Hematologist, Mayo Clinic, tells us how the outcomes of the TOURMALINE-MM3 study may impact the way he treats multiple myeloma (MM) patients who have had at least one prior therapy
James McCloskey, MD, describes how the FLT3 mutation influences treatment decisions in AML
Dr. McCloskey, Interim Chief, Division of Leukemia, Hackensack University Medical Center, John Theurer Cancer Center, discusses how the FLT3 mutation influences treatment plans for acute myelogenous leukemia (AML)
Rafael Fonseca, MD, elaborates on the outcomes of the POLLUX and CASTOR studies in MM
Dr. Fonseca, Hematologist, Mayo Clinic, explains how the POLLUX and CASTOR studies presented at the 2018 ASH Annual Meeting and Exposition shape his thinking regarding the use of daratumumab for multiple myeloma (MM) patients
James McCloskey, MD, speculates on the reliability of the companion diagnostic test for FLT3
Dr. McCloskey, Interim Chief, Division of Leukemia, Hackensack University Medical Center, John Theurer Cancer Center, provides opinion on the reliability of the companion diagnostic test for FLT3 and whether the test may be used to determine treatment in acute myelogenous leukemia (AML)
Rafael Fonseca, MD, discusses frontline multiple myeloma treatment patterns
Dr. Fonseca, Hematologist, Mayo Clinic, tells us about frontline multiple myeloma (MM) treatment patterns and attrition rates in subsequent lines of therapy
Edward Copelan, MD, considers the role of allogeneic transplantation in lymphoma & multiple myeloma
Dr. Copelan, Chair, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, considers how allogeneic transplantation is being optimized for lymphoma and multiple myeloma patients and how does it compares with CAR-T therapies
Edward Copelan, MD, regarding gilteritinib for patients with FLT3+ AML
Dr. Copelan, Chair, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, on how he is currently testing acute myelogenous leukemia (AML) and how he will incorporate newly approved gilteritinib for patients with AML that are FLT3+
Nikhil Munshi, MD, discusses the outcomes of the TOURMALINE-MM3 study in multiple myeloma
Dr. Munshi, Director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Professor of Medicine, Harvard Medical School, explores how the outcomes of the TOURMALINE-MM3 study will or will not change the way multiple myeloma patients who have had at least one prior therapy are treated
Nikhil Munshi, MD, discusses the POLLUX and CASTOR studies regarding the use of daratumumab in MM
Dr. Munshi, Director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Professor of Medicine, Harvard Medical School, discusses how the POLLUX and CASTOR studies impact the use of daratumumab in multiple myeloma patients
Nikhil Munshi, MD, regarding the outcomes of the CA204-142 study from ASH 2018
Dr. Munshi, Director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Professor of Medicine, Harvard Medical School, tells us about the outcomes of the CA204-142 study investigating elotuzumab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma (MM)
Nikhil Munshi, MD, considers how ID2 function impacts oncogenesis in multiple myeloma
Dr. Munshi, Director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Professor of Medicine, Harvard Medical School, explains how ID2 function impacts oncogenesis in multiple myeloma (MM)
Andrew Pecora, MD, shares his thoughts on the necessity of allogeneic transplants to MML patients
Dr. Pecora, Chief Innovation Officer, Professor and Vice President of Cancer Services John Theurer Cancer Center, shares his thoughts on if there will be a day when it may not be necessary to give an allogeneic transplant to multiple myeloma and lymphoma patients
Nizar Bahlis, MD, speculates on the future of anti-BCMA CAR-T cell therapy in MM
Dr. Bahlis, University of Calgary, Calgary, provides opinion on whether anti-BCMA CAR-T cell therapy looks promising as a treatment option for multiple myeloma (MM) patients
Nizar Bahlis, MD, describes current maintenance regimens for multiple myeloma
Dr. Bahlis, University of Calgary, Calgary, discusses current maintenance regimens for multiple myeloma (MM) and how they may change as a result of the clinical studies presented at the ASH 2018 Annual Meeting and Exposition
John Burke, MD, elaborates on the Beat AML umbrella study
Dr. Burke, Hematologist/Oncologist and Associate Chair of the US Oncology Hematology Research Program, Rocky Mountain Cancer Centers, tells us about the design, outcomes and significance of the Beat AML umbrella study
Nizar Bahlis, MD, discusses the outcomes of the TOURMALINE-MM3 study from ASH 2018
Dr. Bahlis, University of Calgary, Calgary, tells us how the outcomes of the TOURMALINE-MM3 study may change the way he treats multiple myeloma (MM)
John Burke, MD, comments on clinical research examining gilteritinib in newly diagnosed AML
Dr. Burke, Hematologist/Oncologist and Associate Chair of the US Oncology Hematology Research Program, Rocky Mountain Cancer Centers, comments on the Phase I study of gilteritinib in combination with induction and consolidation therapy in subjects with newly diagnosed acute myeloid leukemia (AML)
Nizar Bahlis, MD, regarding the impact of the POLLUX and CASTOR studies from ASH 2018
Dr. Bahlis, University of Calgary, Calgary, shares how the POLLUX and CASTOR studies presented at the 2018 ASH Annual Meeting and Exposition shape his thinking regarding the use of daratumumab in multiple myeloma (MM) treatment
John Burke, MD, elaborates on the incorporation of venetoclax into AML treatment regimens
Dr. Burke, Hematologist/Oncologist and Associate Chair of the US Oncology Hematology Research Program, Rocky Mountain Cancer Centers, explains how he plans to incorporate venetoclax into treatment regimen for acute myeloid leukemia (AML) patients
Elizabeth Budde, MD, evaluates the clinical study investigating mosunetuzumab from ASH 2018
Dr. Budde, Assistant Professor in the Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, tells us about the results of the clinical study investigating mosunetuzumab, an anti-CD20/CD3 monoclonal antibody, in relapsed/refractory B-cell non-Hodgkin lymphoma (NHL) patients
John Burke, MD, speaks to the reliability of the FLT3 mutation test
Dr. Burke, Hematologist/Oncologist and Associate Chair of the US Oncology Hematology Research Program, Rocky Mountain Cancer Centers, considers whether the companion diagnostic test for FLT3 is reliable in determining a course of treatment in acute myelogenous leukemia (AML)
Elizabeth Budde, MD, on how City of Hope has overcome logistical hurdles associated with CAR-T
Dr. Budde, Assistant Professor in the Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, explains how her organization has overcome some of the logistical hurdles associated with CAR-T therapies
John Burke, MD, regarding gilteritinib in acute myeloid leukemia treatment
Dr. Burke, Hematologist/Oncologist and Associate Chair of the US Oncology Hematology Research Program, Rocky Mountain Cancer Centers, elaborates on how newly approved gilteritinib will fit into treatment algorithms for patients with acute myeloid leukemia (AML)
Elizabeth Budde, MD, discusses the role of CAR-T therapies in lymphoma treatment algorithms
Dr. Budde, Assistant Professor in the Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, provides opinion on how CAR-T therapies are being incorporated into treatment algorithms for lymphoma
Robert Rifkin, MD, shares his thoughts on if a rituximab biosimilar can replace rituximab
Dr. Rifkin, Hematologist/Oncologist, Associate Chair, US Oncology Hematology Research, Rocky Mountain Cancer Centers, shares his thoughts on if a rituximab biosimilar can replace rituximab in follicular lymphoma treatment regimens and beyond
Robert Rifkin, MD, discusses the rationale for genetically profiling AML patients
Dr. Rifkin, Hematologist/Oncologist, Associate Chair, US Oncology Hematology Research, Rocky Mountain Cancer Centers, discusses the rationale for genetically profiling Acute Myelogenous Leukemia (AML) patients, which patients should be profiled, and how actionable the results are
Robert Rifkin, MD, explains whether or not anti-BCMA CAR-T cell therapy looks promising
Dr. Rifkin, Hematologist/Oncologist, Associate Chair, US Oncology Hematology Research, Rocky Mountain Cancer Centers, explains whether or not anti-BCMA CAR-T cell therapy looks promising as a treatment for multiple myeloma patients
Robert Rifkin, MD, discusses the outcomes of the TOURMALINE-MM3 study
Dr. Rifkin, Hematologist/Oncologist, Associate Chair, US Oncology Hematology Research, Rocky Mountain Cancer Centers, on if the outcomes of the TOURMALINE-MM3 study will or will not change the way multiple myeloma patients are treated
Robert Rifkin, MD, talks about what clinical data could change the way multiple myeloma is treated
Dr. Rifkin, Hematologist/Oncologist, Associate Chair, US Oncology Hematology Research, Rocky Mountain Cancer Centers, talks about what clinical data has been presented at ASH could change the way penta-refractory multiple myeloma patients are treated
Ravi Vij, MD, on molecular testing and acute myelogenous leukemia
Dr. Vij, Professor of Medicine, Oncology Division, Bone Marrow Transplantation & Leukemia, Washington University School of Medicine, describes how molecular tests are being incorporated into acute myelogenous leukemia (AML) treatment algorithms
Samer Khaled, MD, tells us about the MEDALIST study examining myelodysplastic syndrome
Assistant Clinical Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, describes the results of the MEDALIST study and how it will impact the way anemia is treated in myelodysplastic syndrome (MDS) patients
Ravi Vij, MD, considers anti-BCMA CAR-T cell therapy in multiple myeloma
Dr. Vij, Professor of Medicine, Oncology Division, Bone Marrow Transplantation & Leukemia, Washington University School of Medicine, considers anti-BCMA CAR-T cell therapy as a promising treatment option for multiple myeloma (MM) patients
Ravi Vij, MD, discusses current maintenance regimens for multiple myeloma
Dr. Vij, Professor of Medicine, Oncology Division, Bone Marrow Transplantation & Leukemia, Washington University School of Medicine, elaborates on current maintenance regimens for multiple myeloma patients and how clinical studies presented at ASH 2018 may influence these regimens
Samer Khaled, MD, on incorporating venetoclax into treatment regimens for AML
Dr. Khaled, Assistant Clinical Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, on incorporating venetoclax into treatment regimens for acute myeloid leukemia (AML) patients
Ravi Vij, MD, shares details regarding his clinical study presented at ASH 2018
Dr. Vij, Professor of Medicine, Oncology Division, Bone Marrow Transplantation & Leukemia, Washington University School of Medicine, tells us about the outcomes of his study investigating ixazomib, revlimid, and dexamethasone consolidation
Samer Khaled, MD, regarding gilteritinib in treatment of acute myelogenous leukemia
Dr. Khaled, Assistant Clinical Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, considers how he will use newly FDA approved Xospata (gilteritinib) for patients with acute myelogenous leukemia (AML)
Samer Khaled, MD, shares details of his study examining the use of CAR-T therapy in ALL
Dr. Khaled, Assistant Clinical Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, tells us about the outcomes of his study examining the use of CAR-T therapy in acute lymphoblastic leukemia (ALL) at the ASH 2018 Annual Meeting and Exposition
Ravi Vij, MD, regarding the POLLUX and CASTOR clinical studies in multiple myeloma
Dr. Vij, Professor of Medicine, Oncology Division, Bone Marrow Transplantation & Leukemia, Washington University School of Medicine, elaborates on the POLLUX and CASTOR studies and whether they shape his thinking regarding the use of daratumumab in the treatment of multiple myeloma (MM)
Andrzej Jakubowiak, MD, shares thoughts on the POLLUX and CASTOR clinical studies
Dr. Jakubowiak, Professor of Medicine Director, Myeloma Program, University of Chicago Medical Center, provides opinion on how the POLLUX and CASTOR studies shaped his thinking regarding the use of daratumumab for the treatment of multiple myeloma (MM)
Andrzej Jakubowiak, MD, PhD, discusses maintenance regimens in treatment of multiple myeloma
Dr. Jakubowiak, Professor of Medicine Director, Myeloma Program, University of Chicago Medical Center, shares how maintenance regimens for multiple myeloma (MM) patients may change as a result of clinical presentations at the ASH 2018 Annual Meeting and Exposition
Andrzej Jakubowiak, MD, PhD, regarding the ALCYONE trial presented at ASH 2018
Dr. Jakubowiak, Professor of Medicine Director, Myeloma Program, University of Chicago Medical Center, tells us about the ALCYONE study examining the addition of daratumumab to bortezomib, melphalan, and prednisone in patients with transplant-ineligible newly diagnosed multiple myeloma (MM)
Andrzej Jakubowiak, MD, discusses the outcomes of the GRIFFIN study from ASH 2018
Dr. Jakubowiak, Professor of Medicine Director, Myeloma Program University of Chicago Medical Center, tells us about the outcomes of the GRIFFIN study, a Phase 2 clinical study examining daratumumab, bortezomib, lenalidomide, and dexamethasone versus RVD in newly diagnosed multiple myeloma (MM) patients
Chadi Nabhan, MD, MBA, on the role of advanced practice practitioners
Dr. Nabhan, VP, Chief Medical Officer, Cardinal Health Specialty Solutions, discusses the role of advanced practice practitioners and why they are often challenging to recruit and retain
Chadi Nabhan, MD, MBA, shares what is being done to prevent oncologist burnout
Dr. Nabhan, VP, Chief Medical Officer, Cardinal Health Specialty Solutions, tells us what is being done to prevent oncologist burnout and make the field more attractive to new recruits
Chadi Nabhan, MD, MBA, discusses the key factors contributing to physician burnout
Dr. Nabhan, VP, Chief Medical Officer, Cardinal Health Specialty Solutions, shares the primary driving factors contributing to physician burnout
Chadi Nabhan, MD, MBA, regarding the risks related to two-sided payment agreements
Dr. Nabhan, VP, Chief Medical Officer, Cardinal Health Specialty Solutions, discusses the potential risks faced by oncologists if they enter into a two-sided payment agreement with CMS
Chadi Nabhan, MD, MBA, elaborates on the skepticism regarding MACRA
Dr. Nabhan, VP, Chief Medical Officer, Cardinal Health Specialty Solutions, considers why oncologists remain skeptical about the overall benefits of MACRA
Sundar Jagannath, MD, discusses the role of checkpoint inhibitors in treatment of MM
Dr. Jagannath, Professor of Medicine, Hematology and Medical Oncology, Mount Sinai School of Medicine, offers opinion on the role of checkpoint inhibitors in the treatment of multiple myeloma (MM)
Sundar Jagannath, MD, regarding proteasome inhibitors in the treatment of MM
Dr. Jagannath, Professor of Medicine, Hematology and Medical Oncology, Mount Sinai School of Medicine, on whether data supports the integration of proteasome inhibitors in treatment algorithms for multiple myeloma (MM)
Maria-Victoria Mateos, MD, elaborates on the TOURMALINE-MM3 presented at ASH 2018
Dr. Mateos, Associate Professor of Medicine, University of Salamanca, gives her impressions of the TOURMALINE-MM3 study presented at the 2018 ASH Annual Meeting and Exposition and whether it will change maintenance following ASCT in newly diagnosed multiple myeloma (MM) patients
Maria-Victoria Mateos, MD, on the addition of daratumumab to revlimid/dexamethasone in MM
Dr. Mateos, Associate Professor of Medicine, University of Salamanca, explains how the addition of daratumumab to revlimid/dexamethasone enhances outcomes in newly diagnosed multiple myeloma (MM) patients
Sundar Jagannath, MD, considers maintenance regimens for multiple myeloma (MM) patients
Dr. Jagannath, Professor of Medicine, Hematology and Medical Oncology, Mount Sinai School of Medicine, offers opinion on clinical presentations from the ASH 2018 Annual Meeting and Exposition and the influence on maintenance regimens for multiple myeloma (MM) patients
Sundar Jagannath, MD, elaborates on the outcomes of CA204-142 in MM
Dr. Jagannath, Professor of Medicine, Hematology and Medical Oncology, Mount Sinai School of Medicine, tells us about the outcomes of the CA204-142 study investigating elotuzumab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma (MM)
Maria-Victoria Mateos, MD, regarding the CASTOR trial presented at ASH 2018
Dr. Mateos, Associate Professor of Medicine, University of Salamanca, tells us about the design and outcomes of the CASTOR study investigating bortezomib and dexamethasone +/- daratumumab in relapsed/refractory multiple myeloma
Maria-Victoria Mateos, MD, shares outcomes from the ALCYONE study in MM
Dr. Mateos, Associate Professor of Medicine, University of Salamanca, tells us about the results of the ALCYONE study looking at daratumumab plus bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone in transplant-ineligible newly diagnosed multiple myeloma (MM) patients
Jeff Sharman, MD, shares his thoughts on rituximab biosimilars in follicular lymphoma
Dr. Sharman, Director of Research, Willamette Valley Cancer Institute, Medical Director of Hematology Research, The US Oncology Network, shares his thoughts on if a rituximab biosimilar can replace rituximab in follicular lymphoma treatment regimens and beyond
Lorenz Trumper, MD, discusses the results of ECHELON-2 in frontline PTCL
Dr. Trumper, Professor of Internal Medicine and Chairman of the Department of Hematology and Oncology, Georg August University of Göttingen, discusses the results of ECHELON-2 and whether the results will change the way frontline peripheral T-cell lymphoma (PTCL) patients will be treated
Jeff Sharman, MD, on the outcomes of CAPTIVATE study investigating ibrutinib and venetoclax
Dr. Sharman, Director of Research, Willamette Valley Cancer Institute, Medical Director of Hematology Research, The US Oncology Network, on the outcomes of the CAPTIVATE study investigating ibrutinib and venetoclax in the treatment of front line Chronic Lymphocytic Leukemia (CLL)
Jeff Sharman, MD, on how important the CLL-14 study is in determining CLL treatment strategies
Dr. Sharman, Director of Research, Willamette Valley Cancer Institute, Medical Director of Hematology Research, The US Oncology Network, explains how important the CLL-14 study is in determining Chronic Lymphocytic Leukemia (CLL) treatment strategies
Lorenz Trumper, MD, on the current standard of care for the frontline treatment of PTCL
Dr. Trumper, Professor of Internal Medicine and Chairman of the Department of Hematology and Oncology, Georg August University of Göttingen, discusses what the current standard of care for the frontline treatment of patients with peripheral T-cell lymphoma (PTCL)
Jeff Sharman, MD, discusses the phase 3 study investigating ibrutinib in younger CLL patients
Dr. Sharman, Director of Research, Willamette Valley Cancer Institute, Medical Director of Hematology Research, The US Oncology Network, about the outcomes of the phase 3 study presented here at ASH investigating 1st line ibrutinib + rituximab versus FCR in younger Chronic Lymphocytic Leukemia (CLL) patients
Lorenz Trumper, MD, speaks on the differences between B-Cell and T-Cell lymphomas
Dr. Trumper, Professor of Internal Medicine and Chairman of the Department of Hematology and Oncology, Georg August University of Göttingen, speaks on the differences between B-Cell and T-Cell lymphomas and what drives the design of clinical trials
Jeff Sharman, MD, discusses the phase 3 study investigating ibrutinib in older CLL patients
Dr. Sharman, Director of Research, Willamette Valley Cancer Institute, Medical Director of Hematology Research, The US Oncology Network, tells us about the outcomes of the phase 3 study presented here at ASH investigating 1st line ibrutinib +/- rituximab versus bendamustine plus rituximab in older Chronic Lymphocytic Leukemia (CLL) patients
Swaminathan P. Iyer, MD, regarding improvements in the treatment of CTCL
Dr. Iyer, Professor, Department of Lymphoma and Myeloma, Division of Cancer Medicine Division, MD Anderson Cancer Center, discusses improvements being made in the treatment of cutaneous T-cell lymphoma (CTCL)
Swaminathan P. Iyer, MD, shares exciting studies regarding the treatment of PTCL from ASH 2018
Dr. Iyer, Professor, Department of Lymphoma and Myeloma, Division of Cancer Medicine Division, MD Anderson Cancer Center, offers opinion on impressive studies regarding the treatment of peripheral T-cell lymphoma (PTCL) presented at the 2018 ASH Annual Meeting and Exposition
Swaminathan P. Iyer, MD, on the outcomes of the ECHELON-2 study in PTCL
Dr. Iyer, Professor, Department of Lymphoma and Myeloma, Division of Cancer Medicine Division, MD Anderson Cancer Center, tells us about the study design and outcomes of the ECHELON-2 study in peripheral T-cell lymphoma (PTCL)
Andre Goy, MD, comments on the long-term outcome of acalabrutinib in MCL
Dr. Goy, Chairman and Director of John Theurer Cancer Center, Chief of the Division of Lymphoma, Hackensack University Medical Center, discusses the long-term outcomes of acalabrutinib in mantle cell lymphoma (MCL)
Andre Goy, MD, on immunotherapy and the treatment of hematologic malignancies
Dr. Goy, Chairman and Director of John Theurer Cancer Center, Chief of the Division of Lymphoma, Hackensack University Medical Center, explains how immunotherapies are being integrated into the treatment of hematologic malignancies
Andre Goy, MD, considers checkpoint inhibitors in hematologic malignancies
Dr. Goy, Chairman and Director of John Theurer Cancer Center, Chief of the Division of Lymphoma, Hackensack University Medical Center, elaborates on whether checkpoint inhibitors (i.e. ipilimumab and nivolumab) can be used as consolidation following ASCT in hematologic malignancies
Andre Goy, MD, discusses his real-world experience using axi-cel CAR-T cell therapy
Dr. Goy, Chairman and Director of John Theurer Cancer Center, Chief of the Division of Lymphoma, Hackensack University Medical Center, offers opinion on his real-world experience using axicabtagene ciloleucel (axi-cel) CAR-T cell therapy to treat lymphoma
Andre Goy, MD, on research regarding the use of axi-cel CAR-T cell therapy in DLBCL
Dr. Goy, Chairman and Director of John Theurer Cancer Center, Chief of the Division of Lymphoma, Hackensack University Medical Center, elaborates on the design and outcomes of a study looking at the use of axicabtagene ciloleucel (axi-cel) CAR-T cell therapy for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) presented at the ASH 2018 Annual Meeting and Exposition
Tatyana Feldman, MD, regarding improvements in the treatment of CTCL
Dr. Feldman, Hematology & Oncology, Hackensack University Medical Center, John Theurer Cancer Center, discusses improvements in the treatment of cutaneous T-cell lymphoma (CTCL) from the 2018 ASH Annual Meeting and Exposition
Tatyana Feldman, MD, on exciting studies from ASH 2018 regarding the treatment of PTCL
Dr. Feldman, Hematology & Oncology, Hackensack University Medical Center, John Theurer Cancer Center, provides opinion on impressive studies regarding the treatment of peripheral T-cell lymphoma (PTCL) presented at the 2018 ASH Annual Meeting and Exposition
Frederick Locke, MD, on whether CAR-T therapies will be expanded into solid tumors
Dr. Locke, Program Co-Leader, Immunology Moffitt Cancer Center, shares his thoughts on whether CAR-T therapies will be expanded into solid tumors
Frederick Locke, MD, on the management of toxicity withs with CAR-T therapies
Dr. Locke, Program Co-Leader, Immunology Moffitt Cancer Center, discusses how to manage toxicities with CAR-T therapies
Julie Vose, MD, on management of common toxicities with CAR-T therapies
Dr. Vose, Professor, Internal Medicine Division of Oncology & Hematology University of Nebraska Medical Center, talks about the most common toxicities associated with CAR-T therapies and how to manage them
David Siegel, MD, explains the results of MM014 study presented at ASH
Dr. Siegel, Hematologist/Oncologist, Hackensack University Medical Center, John Theurer Cancer Center, explains the results of the MM014 study presented here at ASH
Julie Vose, MD, discusses improvements made in the delivery of CAR-T therapies in lymphoma
Dr. Vose, Professor, Internal Medicine Division of Oncology & Hematology University of Nebraska Medical Center, discusses what improvements are being made to the delivery of CAR-T therapies to improve outcomes in the treatment of lymphoma
Frederick Locke, MD, on what improvements to turn around time with CAR-T therapies
Dr. Locke, Program Co-Leader, Immunology Moffitt Cancer Center, on what improvements to turn around time Moffitt has implemented to help make CAR-T therapies more convenient and effective
David Siegel, MD, discusses anti-BCMA CAR-T cell therapy for multiple myeloma patients
Dr. Siegel, Hematologist/Oncologist, Hackensack University Medical Center, John Theurer Cancer Center, shares his thoughts on anti-BCMA CAR-T cell therapy and if it looks promising as a treatment for multiple myeloma patients
Frederick Locke, MD, discusses how to integrate CAR-T with stem cell transplant
DR. Locke, Program Co-Leader, Immunology Moffitt Cancer Center, discusses how to integrate CAR-T with stem cell transplant and therapeutic combinations to treat lymphoma in the future
Andre Goy, MD, on responses & outcomes when treating lymphoma with CAR-T therapies
Dr. Goy, Chairman and Director of John Theurer Cancer Center, Chief of the Division of Lymphoma, Hackensack University Medical Center, provides opinion on the responses and outcomes when treating lymphoma with CAR-T therapies and whether they will become a significant part of the treatment regimens
Tatyana Feldman, MD, shares outcomes of the ECHELON-2 study in PTCL
Dr. Feldman, Hematology & Oncology, Hackensack University Medical Center, John Theurer Cancer Center, tell us about the study design and outcomes of the ECHELON-2 study in peripheral T-cell lymphoma (PTCL)
David Siegel, MD, talks about the TOURMALINE-MM3 study and the treatment of multiple myeloma
Dr. Siegel, Hematologist/Oncologist, Hackensack University Medical Center, John Theurer Cancer Center, talks about how the outcomes of the TOURMALINE-MM3 study will or will not change how multiple myeloma patients are treated who have had at least one prior therapy
Tatyana Feldman, MD, offers opinion on the ECHELON-2 study in PTCL
Dr. Feldman, Hematology & Oncology, Hackensack University Medical Center, John Theurer Cancer Center, speculates on whether the ECHELON-2 study is game-changing for patients with peripheral T-cell lymphoma (PTCL)
Frederick Locke, MD, on the use of CAR-T therapies in leukemia and lymphoma
Dr. Locke, Program Co-Leader, Immunology Moffitt Cancer Center, shares his thoughts on whether CAR-T therapies are showing impressive results in leukemia and lymphoma, and if real world evidence is matching up well with clinical trial results
Tatyana Feldman, MD, on unmet needs in peripheral T-cell lymphoma (PTCL)
Dr. Feldman, Hematology & Oncology, Hackensack University Medical Center, John Theurer Cancer Center, describes unmet needs in the treatment of peripheral T-cell lymphoma (PTCL)
Julie Vose, MD, on if CAR-T therapies are showing impressive results in lymphoma
Dr. Vose, Professor, Internal Medicine Division of Oncology & Hematology University of Nebraska Medical Center, explains if CAR-T therapies are showing impressive results in lymphoma, and whether real world evidence is matching up well with clinical trial results
Andrew Pecora, MD, tells us about the results of the CPIT trial presented here at ASH
Dr. Pecora, Chief Innovation Officer, Professor and Vice President of Cancer Services, John Theurer Cancer Center, tells us about the results of the CPIT trial presented here at ASH
David Siegel, MD, shares his thoughts on the daratumamab studies presented at ASH 2018
Dr. Siegel, Hematologist/Oncologist, Hackensack University Medical Center, John Theurer Cancer Center, shares his thoughts on the daratumamab studies presented at the meeting
Julie Vose, MD, tells us about the results of the AUGMENT study in relapsed/refractory indolent NHL
Dr. Vose, Professor, Internal Medicine Division of Oncology & Hematology University of Nebraska Medical Center, tells us about the results of the AUGMENT study looking at lenalidomide and rituximab in the treatment of relapsed/refractory indolent Non-Hodgkin’s Lymphoma (NHL)
Julie Vose, MD, discusses whether polatuzumab improves outcomes in DLBCL patients
Dr. Vose, Professor Internal Medicine Division of Oncology & Hematology University of Nebraska Medical Center, discusses whether adding polatuzumab to bendamustine and rituximab improve outcomes in diffuse large B-cell lymphoma (DLBCL) patients
Andre Goy, MD, discusses how CAR-T therapies are being integrated into the treatment of large B-Cell lymphoma
Dr. Goy, Chairman and Director of John Theurer Cancer Center, Chief of the Division of Lymphoma, Hackensack University Medical Center, discusses how CAR-T therapies are being integrated into the treatment of relapsed/refractory large B-Cell lymphoma
Ravi Vij, MD, on the outcomes of the TOURMALINE-MM3 study in multiple myeloma
Ravi Vij, MD, Professor of Medicine, Oncology Division, Bone Marrow Transplantation & Leukemia, Washington University School of Medicine, shares how the outcomes of the TOURMALINE-MM3 study will impact the way he treats multiple myeloma (MM) patients
Swaminathan Padmanabhan Iyer, MD, on if ECHELON-2 study is game changing for patients with PTCL
Dr. Iyer, Professor, Department of Lymphoma and Myeloma, MD Anderson Cancer Center, on if ECHELON-2 study is game changing for patients with Peripheral T-Cell Lymphoma (PTCL)
Keith Pratz, MD, discusses venetoclax in treatment of acute myeloid leukemia (AML)
Dr. Pratz, Assistant Professor of Oncology , Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, shares how he plans to incorporate venetoclax into treatment regimens for acute myeloid leukemia (AML) patients
James McClosky, MD, on using newly FDA approved gilteritinib for patients with AML
Dr. McClosky, Interim Chief, Division of Leukemia, Hackensack University Medical Center, John Theurer Cancer Center, on using newly FDA approved gilteritinib for patients with AML
Peter Vorhees, MD, discusses the outcomes of the GRIFFIN trial in multiple myeloma
Peter Vorhees, MD, Director of Outreach and Clinical Operations, Department of Hematologic Oncology and Blood Diosrders, Levine Cancer Institute, discusses the outcomes of the GRIFFIN trial in multiple myeloma at ASH 2018
Daniel J. DeAngelo, MD, PhD, offers his opinion on the clinical development of BLU-285
Dr. DeAngelo elaborates on the clinical development of BLU-285 moving forward
Daniel J. DeAngelo, MD, PhD, on the phase 1 study of BLU-285 in advanced systemic mastocytosis
Dr. DeAngelo expands on the outcomes from the phase 1 study of BLU-285 in advanced systemic mastocytosis
Andrew Lane, MD, PhD, describes the efficacy outcomes of SL-401 consolidation therapy in AML
Dr. Lane elaborates on the efficacy outcomes of SL-401 consolidation therapy in patients with acute myeloid leukemia (AML)
Robert Soiffer, MD, discusses ways to enhance the activity of Il-2 in chronic GVHD
Dr. Soiffer discusses ways to enhance the activity of Il-2 in chronic graft versus host disease (GVHD)
Ching-Hon Pui, MD, speculates on the use of CAR T-cell therapy in pediatric ALL patients
Dr. Pui tells us how he sees CAR T-cell therapy being used in pediatric acute lymphocytic leukemia (ALL) patients
Ching-Hon Pui, MD, explains how precision medicine is changing the way pediatric ALL is treated
Dr. Pui describes how precision medicine is changing the way we treat pediatric acute lymphocytic leukemia (ALL) today
Ching-Hon Pui, MD, on whether the FDA should accept minimal residual disease as a surrogate endpoint
Dr. Pui offers opinion on whether the FDA should accept minimal residual disease as a surrogate endpoint for regulatory approval
Ching-Hon Pui, MD, discusses minimal residual disease in pediatric and adult ALL patients
Dr. Pui elaborates on the optimal way to use minimal residual disease in pediatric and adult acute lymphocytic leukemia (ALL) patients
Jesus San-Miguel, MD, on the role of daratumumab in the front-line setting in multiple myeloma (MM)
Dr. San-Miguel discusses the role of daratumumab in the front-line setting in multiple myeloma (MM) patients
Jorge Cortes, MD, shares data presented at ASH 2017 regarding bosutinib in CML treatment
Dr. Cortes tells us about the clinical data presented at ASH 2017 regarding treatment of front-line chronic myelogenous leukemia (CML) with bosutinib
Brad S. Kahl, MD, on the evidence for maintenance rituximab as a front-line treatment option in FLL
Dr. Kahl elaborates on the evidence for using rituximab maintenance as a front-line treatment option with bendamustine-rituxan in follicular lymphoma (FL) patients
James R. Downing, MD, explains the mission of St. Jude Children’s Research Hospital
Dr. Downing shares how the mission of St. St. Jude Children’s Research Hospital is benefiting the pediatric cancer patient community
Andrew Lane, MD, PhD, on how frequently clinicians interact with frail AML patients
Dr. Lane describes how often clinicians will see frail acute myeloid leukemia (AML) patients and how this patient population should be managed
Andrew Lane, MD, PhD, on treatment approaches when managing frail AML patients
Dr. Lane offers his opinion on agents or treatment approaches a clinician should seek when managing frail acute myeloid leukemia (AML) patients
Andrew Lane, MD, PhD, offers strategies for clinicians when treating frail AML patient populations
Dr. Lane discusses strategies for frail acute myeloid leukemia (AML) patients who do not qualify for intensive therapy
Andrew Lane, MD, PhD, shares outcomes from the phase 2 study of SL-401 in patients with BPDCN
Dr. Lane discusses the outcomes from the pivotal phase 2 study of SL-401 in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN)
Jesus San-Miguel, MD, on daratumumab in a first-line setting as a result of the ALCYON study
Dr. San-Miguel shares his thoughts on whether daratumumab should be adopted in the first-line setting outside of the U.S. as a result of the ALCYON study
Jesus San-Miguel, MD, explains the efficacy and safety outcomes of the ALCYON clinical study
Dr. San-Miguel elaborates on the efficacy and safety outcomes of the ALCYON clinical study
Jens G. Lohr, MD, PhD, discusses the kind of information we can gather from liquid biopsy
Dr. Lohr elaborates on the kind of information we can get from liquid biopsy and how this compares to the information we can gather from bone marrow biopsy
Jens G. Lohr, MD, PhD, on utilizing liquid biopsy and how it compares to bone marrow biopsy
Dr. Lohr explains why we should use liquid biopsy and how it compares to bone marrow biopsy
James Essell, MD, discusses the concerns for patients receiving allogeneic transplantations
Dr. Essell elaborates on the conners for patients receiving allogeneic transplantations today
James Essell, MD, on how allogeneic transplantation is incorporated into hematologic malignancy
Dr. Essell explains how allogeneic transplantation is incorporated into hematologic malignancy today
Brad S. Kahl, MD, considers the unmet medical needs in treatment of Hodgkin lymphoma
Dr. Kahl offers his opinion on the unmet needs in Hodgkin lymphoma
Brad S. Kahl, MD, discusses the ECHELON-1 phase 3 clinical trial in Hodgkin lymphoma
Dr. Kahl shares information on the ECHELON-1 phase 3 clinical trial in Hodgkin lymphoma presented at ASH 2017
Brad S. Kahl, MD, tells us about his study evaluating ADCT-402 in DLBCL
Dr. Kahl elaborates on his study evaluating ADCT-402 in diffuse large B-cell lymphoma (DLBCL)
Jorge Cortes, MD, on how generic imatinib is being adopted as an alternative to branded imatinib
Dr. Cortes elaborates on how generic imatinib is being adopted in clinical studies as an alternative to branded imatinib
Jorge Cortes, MD, on what was discussed at ASH 2017 regarding treatment discontinuation in AML
Dr. Cortes shares what was talked about at ASH 2017 regarding treatment discontinuation in acute myeloid leukemia (AML) patients
Simon Rule, MD, considers the clinical development plan with Imbruvica in mantle cell lymphoma (MCL)
Dr. Rule shares his thoughts on the clinical development plan with Imbruvica (ibrutinib) in mantle cell lymphoma (MCL)
Simon Rule, MD, discusses the ibrutinib data in relapsed/refractory MCL presented at ASH 2017
Dr. Rule tells us about the presentation of the ibrutinib data in relapsed/refractory mantle cell lymphoma (MCL) presented at ASH 2017
Edward A. Copelan, MD, shares highlights from ASH 2017 regarding treatment of acute myeloid leukemia
Dr. Copelan offers his opinion on the highlights presented at ASH 2017 in the treatment of acute myeloid leukemia (AML)
Edward A. Copelan, MD, on allogeneic transplantation & CAR T-cell therapy in lymphoma and myeloma
Dr. Copelan elaborates on how allogeneic transplantation is being optimized for lymphoma and myeloma patients and how it compares with CAR T-cell therapy
Edward A. Copelan, MD, considers whether azacitidine can be used for induction in AML
Dr. Copelan on whether azacitidine can be used for induction in acute myeloid leukemia (AML)
James R. Downing, MD, discusses the significant studies presented at ASH 2017
Dr. Downing considers the significant clinical studies performed by physicians at St. Jude Children’s Research Hospital and presented at ASH 2017
James R. Downing, MD, on the evolution of St. Jude Children’s Research Hospital
Dr. Downing shares how St. Jude Children’s Research Hospital has been evolving to better meet the needs of pediatric cancer patients
John Burke, MD, on rituximab as an effective strategy after 1st line bendamustine-rituximab in FL
Dr. Burke, on whether rituximab is an effective maintenance strategy after 1st line bendamustine-rituximab in previously untreated follicular lymphoma patients
Keith Pratz, MD, on the proportion of AML patients who fall into the frail category
Dr. Pratz describes the proportion of acute myeloid leukemia (AML) patients who fall into the category of frail
Keith Pratz, MD, explains how he is incorporating Vyxeos into his treatment of AML patients
Dr. Pratz tells us how he is incorporating Vyxeos (liposomal daunorubicin and cytarabine) into his practice for acute myeloid leukemia (AML) patients
Keith Pratz, MD, suggests strategies for clinicians when treating frail AML patients
Dr. Pratz offers his opinion on strategies for treating frail acute myeloid leukemia (AML) patients who do not quality for intensive therapy
Keith Pratz, MD, on exciting clinical data regarding FTL3 tyrosine kinase inhibitors in AML patients
Dr. Pratz evaluates some of the exciting clinical data with FLT3 tyrosine kinase inhibitors in acute myeloid leukemia (AML) patients presented at ASH 2017
Keith Pratz, MD, shares the outcome of the venetoclax study in treatment-naive AML patients
Dr. Pratz shares the outcomes of the venetoclax with decitabine or azacitidine study in treatment-naive acute myeloid leukemia (AML) patients
Keith Pratz, MD, on combining ivosidenib or enasidenib with chemotherapy in AML
Dr. Pratz considers whether we can combine ivosidenib or enasidenib with standard induction chemotherapy in newly diagnosed acute myeloid leukemia (AML) patients
Keith Pratz, MD, tells us about the epidemiology and cytogenetic risk associated with AML
Dr. Pratz discusses the epidemiology and cytogenetic risk associated with acute myeloid leukemia (AML)
Fredrick B. Hagemeister, MD, on the exploration of CAR T-cell therapies in various lymphoma types
Dr. Hagemeister offers his opinion on the effectiveness of CAR T-cell therapies outside of large cell lymphomas and whether we can apply this technology to other patient types
Fredrick B. Hagemeister, MD, describes how PD-1 inhibitors are being incorporated into FL treatment
Dr. Hagemeister explains how PD-1 inhibitors are being incorporated into follicular lymphoma (FL) treatment programs
Fredrick B. Hagemeister, MD, on managing toxicities associated with CAR T-cell therapies
Dr. Hagemeister on the safety of CAR T-cell therapies for lymphoma patients and recommendations for managing toxicities associated with these therapies
Fredrick B. Hagemeister, MD, on what we should know about CAR T-cell therapies
Dr. Hagemeister shares what physicians should know about the development of CAR T-cell therapies in lymphoid malignancies
Andrew Lane, MD, PhD, on minimal residual disease and AML treatment decisions
Dr. Lane discusses how minimal residual disease is being integrated into treatment decision making in acute myeloid leukemia (AML) patients
John Burke, MD, lists the top findings from ASH 2017 regarding lymphoid malignancies
Dr. Burke, shares his thoughts on the top findings at ASH 2017 regarding lymphoid malignancies
John Burke, MD, on combination atezolizumab, obinutuzumab, and bendamustine in follicular lymphoma
Dr. Burke, comments on the safety and efficacy of adding atezolizumab to obinutuzumab and bendamustine in patients with previously untreated follicular lymphoma
Habte Yimer, MD, on daratumumab, cyclophosphamide, bortezomib, & dexamethasone in relapsed MM
Dr. Yimer considers the safety of combination daratumumab, cyclophosphamide, bortezomib, and dexamethasone in previously untreated and relapsed multiple myeloma (MM) patients
Habte Yimer, MD, considers the impact of combination obinutuzumab and bendamustine on CLL patients
Dr. Yimer on how the combination of obinutuzumab and bendamustine improves outcomes, quality of life and symptoms when given to untreated chronic lymphocytic leukemia (CLL) patients
Martin Hutchings, MD, details the role of PET in the management of Hodgkin’s lymphoma
Dr. Hutchings shares his thoughts on the role of PET in the treatment and management of Hodgkin’s lymphoma
Martin Hutchings, MD, considers how the ECHELON-1 study could be practice changing
Dr. Hutchings discusses how the results of the ECHELON-1 Phase 3 study in untreated Stage 3 or 4 Hodgkin’s lymphoma might change current practices
Eunice Wang, MD, shares exciting data for acute myeloid leukemia (AML) presented at ASH 2017
Dr. Wang tells us what exciting clinical data for acute myeloid leukemia (AML) patients was presented at ASH 2017
Eunice Wang, MD, considers approaches for clinicians when managing frail AML patients
Dr. Wang, discusses what type of agents or treatment approaches a clinician should seek when managing frail acute myeloid leukemia (AML) patients
Eunice Wang, MD, on incorporating Vyxeos (liposomal daunorubicin and cytarabine) in AML treatment
Dr. Wang, tells us how she is incorporating Vyxeos (liposomal daunorubicin and cytarabine) into her acute myeloid leukemia (AML) treatment strategy
Eunice Wang, MD, on strategies for frail AML patients who do not qualify for intensive therapy
Dr. Wang, suggests strategies for clinicians with frail acute myeloid leukemia (AML) patients who do not quality for intensive therapy
Eunice Wang, MD, on how minimal residual disease is being integrated into treatment decisions in AML
Dr. Wang elaborates on how minimal residual disease is being integrated into treatment decision making in acute myeloid leukemia (AML) patients
Michael Boxer, MD, on the effectiveness of fostamatinib in the maintenance of ITP responses
Dr. Boxer considers whether fostamatinib is effective in the maintenance of ITP responses
Parameswaran Hari, MD, MRCP, MS, considers the remaining unmet medical needs in MM
Dr. Hari describes the remaining major unmet medical needs in the treatment of multiple myeloma (MM) and the proportion of his patients that fall into this unmet need category
Parameswaran Hari, MD, MRCP, MS, discusses the clinical relevance of minimal residual disease
Dr. Hari elaborates on the clinical relevance of minimal residual disease for patients today
Parameswaran Hari, MD, MRCP, MS, provides an update on how MM patients are staged at diagnosis
Dr. Hari tells us how multiple myeloma (MM) patients are staged at initial diagnosis
Parameswaran Hari, MD, MRCP, MS, on promising cellular immunotherapy studies from ASH 2017
Dr. Hari shares his opinion on the most exciting and promising studies regarding cellular immunotherapy presented at ASH 2017
Parameswaran Hari, MD, MRCP, MS, on how the field of immunotherapy is evolving for MM patients
Dr. Hari offers his thoughts on how the field of immunotherapy is evolving for multiple myeloma (MM) patients
Parameswaran Hari, MD, MRCP, MS, on checkpoint inhibitors and MM treatment algorithms
Dr. Hari explains how checkpoint inhibitors are being integrated into multiple myeloma (MM) treatment algorithms today
David Miklos, MD, PhD, on the possible combination of ibrutinib and CAR T-cell therapies
Dr. Miklos considers the possibility that ibrutinib could be used in combination with CAR T-cell therapies when treating aggressive relapsed/refractory lymphomas
David Miklos, MD, PhD, explains how ibrutinib is being studied for the treatment of GVHD
Dr. Miklos shares how ibrutinib is being studied for the treatment of chronic graft versus host disease (GVHD) today
David Miklos, MD, PhD, describes the optimal way to use ibrutinib in the treatment of GVHD
Dr. Miklos outlines the optimal way to use ibrutinib in the treatment of chronic graft versus host disease (GVHD)
David Miklos, MD, PhD, on the outcomes of the ZUMA-1 clinical study
Dr. Miklos tells us about the outcomes of the ZUMA-1 clinical study and the long-term efficacy of CAR T-cell therapy
Michael Boxer, MD, on how obinutuzumab and bendamustine impacts quality of life in CLL patients
Dr. Boxer elaborates on how treating chronic lymphocytic leukemia (CLL) patients with obinutuzumab and bendamustine affects quality of life and symptoms
Michael Boxer, MD, considers broader uses for fostamatinib
Dr. Boxer offers his opinion on broader uses for fostamatinib
Paul Richardson, MD, on the importance of real world evidence (RWE)
Dr. Richardson provides insight into the importance of real world evidence (RWE) and how clinical data compares with actual usage in multiple myeloma patients
Paul Richardson, MD, shares the efficacy outcomes of GSK-916 in relapsed/refractory MM patients
Dr. Richardson describes the efficacy outcomes of the BCMA immune conjugate (GSK-916) in relapsed/refractory multiple myeloma patients
Paul Richardson, MD, on adding CAR T-cell therapy to multiple myeloma treatment algorithms
Dr. Richardson elaborates on adding CAR T-cell therapy into treatment algorithms for multiple myeloma
